A compound of Formula wherein, X is CR 3 or N; R 1 is C 3 -C 7 heterocycloalkyl, heteroaryl, aryl, -O(C 1 -C 6 alkyl), -O(C 3 -C 7 cycloalkyl) or -NR a R b, wherein said C 3 -C 7 heterocycloalkyl and heteroaryl may be further substituted with one to five R f groups; R 2 is hydrogen, -(CH 2) m aryl, -(CH 2) m heteroaryl, -(CH 2) m C 4 -C 7 heterocycloalkyl, C 1 -C 6 alkyl, alkylamino, alkoxy or - CH 2 O(C 1 -C 3 alkyl); R 3 is hydrogen, C 1 -C 3 alkyl, CN, COOH, C 3 -C 7 cycloalkyl, heterocycloalkyl, -NHC C 1 -C 6 alkyl, -(CH 2) m C NR a R b or heteroaryl; R 4 is hydrogen, C 3 -C 7 heterocycloalkyl, C 3 -C 7 cycloalkyl, C 1 -C 6 alkyl, -(CH 2) m phenyl or - (CH 2) m heteroaryl; wherein each R a is independently H or C 1 -C 6 alkyl; each R b is independently H, C 1 -C 6 alkyl, alkoxy, amino, -(CH 2) m C 3 -C 7 cycloalkyl, -(CH 2) m C 3 -C 7 heterocycloalkyl or -(CH 2) m heteroaryl, wherein said C 3 -C 7 heterocycloalkyl and heteroaryl may be further substituted with one to three groups selected from the group consisting of halo, hydroxy, C 1 -C 3 alkyl, amino, oxo, amide, sulfonyl, sulfoxide, sulfoximinyl, alkoxy, CN and acyl; R a and R b together may form a C 3 -C7cycloalkyl, C 3 -C 7 heterocycloalkyl, or heteroaryl ring; wherein each R f is independently selected from the group consisting of C 1 -C 3 alkyl, alkoxy, amino, hydroxyl, alkylamino, amide, urea, oxo, halo, pyrazolyl, imidazolyl, triazolyl, CN, -NHC (C 1 -C 3 alkyl), acyl, sulfonyl, sulfoxide, sulfoximinyl, sulfonamide, amide, -(CH 2) m C 3 -C 7 heterocycloalkyl, -O(C 1 -C 6 alkyl), -C OR a; each m is independently 0, 1, 2 or 3; or a pharmaceutically acceptable salt thereof. X is CR 3 or N; R 1 is C 3 -C 7 heterocycloalkyl, heteroaryl, aryl, -O(C 1 -C 6 alkyl), -O(C 3 -C 7 cycloalkyl) or -NR a R b, wherein said C 3 -C 7 heterocycloalkyl and heteroaryl may be further substituted with one to five R f groups; R 2 is hydrogen, -(CH 2) m aryl, -(CH 2) m heteroaryl, -(CH 2) m C 4 -C 7 heterocycloalkyl, C 1 -C 6 alkyl, alkylamino, alkoxy or - CH 2 O(C 1 -C 3 alkyl); R 3 is hydrogen, C 1 -C 3 alkyl, CN, COOH, C 3 -C 7 cycloalkyl, heterocycloalkyl, -NHC C 1 -C 6 alkyl, -(CH 2) m C NR a R b or heteroaryl; R 4 is hydrogen, C 3 -C 7 heterocycloalkyl, C 3 -C 7 cycloalkyl, C 1 -C 6 alkyl, -(CH 2) m phenyl or - (CH 2) m heteroaryl; wherein each R a is independently H or C 1 -C 6 alkyl; each R b is independently H, C 1 -C 6 alkyl, alkoxy, amino, -(CH 2) m C 3 -C 7 cycloalkyl, -(CH 2) m C 3 -C 7 heterocycloalkyl or -(CH 2) m heteroaryl, wherein said C 3 -C 7 heterocycloalkyl and heteroaryl may be further substituted with one to three groups selected from the group consisting of halo, hydroxy, C 1 -C 3 alkyl, amino, oxo, amide, sulfonyl, sulfoxide, sulfoximinyl, alkoxy, CN and acyl; R a and R b together may form a C 3 -C7cycloalkyl, C 3 -C 7 heterocycloalkyl, or heteroaryl ring; wherein each R f is independently selected from the group consisting of C 1 -C 3 alkyl, alkoxy, amino, hydroxyl, alkylamino, amide, urea, oxo, halo, pyrazolyl, imidazolyl, triazolyl, CN, -NHC (C 1 -C 3 alkyl), acyl, sulfonyl, sulfoxide, sulfoximinyl, sulfonamide, amide, -(CH 2) m C 3 -C 7 heterocycloalkyl, -O(C 1 -C 6 alkyl), -C OR a; each m is independently 0, 1, 2 or 3; or a pharmaceutically acceptable salt thereof.